@article{f4019b740d194eacb964f338bfeef19e,
title = "Re: Lepore et al.: Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings (Ophthalmology. 2018;125:218-226) REPLY",
abstract = "N/A",
keywords = "Bevacizumab, Fluoresceins, Follow-Up Studies, Humans, Infant, Newborn, Intravitreal Injections, Retinopathy of Prematurity, Bevacizumab, Fluoresceins, Follow-Up Studies, Humans, Infant, Newborn, Intravitreal Injections, Retinopathy of Prematurity",
author = "Domenico Lepore",
year = "2018",
doi = "10.1016/j.ophtha.2018.04.012",
language = "English",
volume = "125",
pages = "e71--e72",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "-ELSEVIER SCIENCE INC, 360 PARK AVE SOUTH, NEW YORK, USA, NY, 10010-1710 -Lippincott, Williams & Wilkins:530 Walnut Street:Philadelphia, PA 19106:(800)638-3030, (301)223-2300, EMAIL: orders@lww.com, INTERNET: http://www.lww.com, Fax: (301)223-2320, (301)223-2320",
}